

Application No. 10/089,009

AMENDMENTS TO THE CLAIMS

This listing of claims replaces all prior versions, and listings, of claims in the application.

1. (Previously Presented) A composition comprising an interleukin-2 receptor associated polypeptide, wherein said interleukin-2 receptor associated polypeptide is capable of forming a complex with the monoclonal antibody produced by the hybridoma PTA-82, wherein said interleukin-2 receptor associated polypeptide is expressed by cells selected from the group consisting of Kit-225 cells and YT cells and said interleukin-2 receptor associated polypeptide has a molecular weight of about 32,000 to 34,000 daltons as determined by SDS-PAGE.

2. (Canceled)

3. (Previously Presented) A composition comprising an interleukin-2 receptor associated polypeptide, wherein said interleukin-2 receptor associated polypeptide is capable of forming a complex with the monoclonal antibody produced by the hybridoma PTA-82, wherein said interleukin-2 receptor associated polypeptide is expressed by cells selected from the group consisting of Kit-225 cells and YT cells and said interleukin-2 receptor associated polypeptide has a molecular weight of about 26,000 to 28,000 daltons as determined by SDS-PAGE.

4. (Canceled)

5. (Original) A composition comprising the interleukin-2 receptor associated polypeptide of Claim 1, wherein said interleukin-2 associated polypeptide associates with the interleukin-2R α subunit.

6-8. (Canceled)

9. (Currently Amended) A method for purifying an interleukin-2 receptor associated polypeptide, wherein said method comprises:

(a) providing cells expressing an interleukin-2 receptor and an interleukin-2 receptor associated polypeptide, wherein said interleukin-2 receptor associated polypeptide has a molecular weight of about 32,000 to 34,000 daltons or about 26,000 to 28,000 daltons as determined by SDS-PAGE.

Application No. 10/089,009

- (b) solubilizing the cells to produce a cell extract,
- (c) contacting said cell extract with an anti-interleukin-2 receptor associated polypeptide antibody, wherein said antibody forms a complex with said interleukin-2 receptor associated polypeptide expressed by said cells,
- (d) eluting said interleukin-2 receptor associated polypeptide from the anti-interleukin-2 receptor associated polypeptide antibody complex, and
- (e) isolating said eluted interleukin-2 receptor associated polypeptide.

10. (Canceled)

11. (Previously Presented) The method of Claim 9, wherein said anti-interleukin-2 receptor associated polypeptide antibody is present on an immunoaffinity column.

12. (Previously Presented) The method of Claim 11, wherein said interleukin-2 receptor associated polypeptide bound to said anti-interleukin-2 receptor associated polypeptide antibody is eluted from said column.

13. (Previously Presented) The method of Claim 9, wherein said cells expressing said interleukin-2 receptor and said interleukin-2 receptor associated polypeptide are selected from the group consisting of cell lines expressing interleukin-2R α and cell lines expressing interleukin-2R β subunits.

14. (Original) The interleukin-2 receptor associated polypeptide of Claim 13, wherein said interleukin-2 receptor expressing cells are Kit 225 cells.

15. (Original) A composition comprising an interleukin-2 receptor associated polypeptide purified by the method of Claim 9.

16-22. (Canceled)

23. (Previously Presented) A composition comprising the interleukin-2 receptor associated polypeptide of Claim 3, wherein said interleukin-2 associated polypeptide associates with the interleukin-2 R α subunit.

24-25 (Canceled)

26. (Previously Presented) A composition comprising an interleukin-2 receptor

Application No. 10/089,009

associated polypeptide, wherein said interleukin-2 receptor associated polypeptide is capable of forming a complex with the monoclonal antibody produced by the hybridoma PTA-82, wherein said interleukin-2 receptor associated polypeptide is expressed by Kit-225 cells and said interleukin-2 receptor associated polypeptide has a molecular weight of about 32,000 to 34,000 daltons as determined by SDS-PAGE.

27. (Previously Presented) A composition comprising an interleukin-2 receptor associated polypeptide, wherein said interleukin-2 receptor associated polypeptide is capable of forming a complex with the monoclonal antibody produced by the hybridoma PTA-82, wherein said interleukin-2 receptor associated polypeptide is expressed by YT cells and said interleukin-2 receptor associated polypeptide has a molecular weight of about 32,000 to 34,000 daltons as determined by SDS-PAGE.

28. (Previously Presented) A composition comprising an interleukin-2 receptor associated polypeptide, wherein said interleukin-2 receptor associated polypeptide is capable of forming a complex with the monoclonal antibody produced by the hybridoma PTA-82, wherein said interleukin-2 receptor associated polypeptide is expressed by Kit-225 cells and said interleukin-2 receptor associated polypeptide has a molecular weight of about 26,000 to 28,000 daltons as determined by SDS-PAGE.

29. (Previously Presented) A composition comprising an interleukin-2 receptor associated polypeptide, wherein said interleukin-2 receptor associated polypeptide is capable of forming a complex with the monoclonal antibody produced by the hybridoma PTA-82, wherein said interleukin-2 receptor associated polypeptide is expressed by YT cells and said interleukin-2 receptor associated polypeptide has a molecular weight of about 26,000 to 28,000 daltons as determined by SDS-PAGE.